195 related articles for article (PubMed ID: 36224402)
1. Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review.
Al Hajji Y; Taylor H; Starkey T; Lee LYW; Tilby M
Br J Cancer; 2022 Nov; 127(10):1827-1836. PubMed ID: 36224402
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
4. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
7. Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
Wankhede D; Grover S; Hofman P
Vaccine; 2023 Mar; 41(11):1791-1798. PubMed ID: 36792435
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis.
Taheri S
Int Urol Nephrol; 2023 Apr; 55(4):791-802. PubMed ID: 36723829
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination in cancer patients: a narrative review.
Seneviratne SL; Yasawardene P; Wijerathne W; Somawardana B
J Int Med Res; 2022 Mar; 50(3):3000605221086155. PubMed ID: 35313761
[TBL] [Abstract][Full Text] [Related]
10. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
11. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
[TBL] [Abstract][Full Text] [Related]
12. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
13. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
14. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
[TBL] [Abstract][Full Text] [Related]
15. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
16. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
17. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
Corti C; Antonarelli G; Scotté F; Spano JP; Barrière J; Michot JM; André F; Curigliano G
Ann Oncol; 2022 Feb; 33(2):158-168. PubMed ID: 34718117
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19.
Kim JY; Kwon JS; Cha HH; Lim SY; Bae S; Kim SH
Korean J Intern Med; 2022 Nov; 37(6):1234-1240. PubMed ID: 36217813
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antibody response after two doses of the Sinovac vaccine and the potential need for booster doses in cancer patients.
Ata S; Cil T; Duman BB; Unal N
J Med Virol; 2022 Jun; 94(6):2487-2492. PubMed ID: 35181932
[TBL] [Abstract][Full Text] [Related]
20. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.
Busà R; Russelli G; Miele M; Sorrentino MC; Di Bella M; Timoneri F; Di Mento G; Mularoni A; Vitulo P; Conaldi PG; Bulati M
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
